297 related articles for article (PubMed ID: 34402193)
21. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
Zhang H; Liu Y; Wang B; Wang C
BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
23. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
25. Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.
Hong B; Yang Y; Guo S; Duoerkun S; Deng X; Chen D; Yu S; Qian W; Li Q; Li Q; Gong K; Zhang N
Oncotarget; 2017 Jul; 8(30):49839-49850. PubMed ID: 28548943
[TBL] [Abstract][Full Text] [Related]
26. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
27. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
[TBL] [Abstract][Full Text] [Related]
28. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
29. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
[TBL] [Abstract][Full Text] [Related]
30. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
31. Bioinformatics analysis and verification of gene targets for renal clear cell carcinoma.
Li F; Jin Y; Pei X; Guo P; Dong K; Wang H; Chen Y; Guo P; Meng LB; Wang Z
Comput Biol Chem; 2021 Jun; 92():107453. PubMed ID: 33636636
[TBL] [Abstract][Full Text] [Related]
32. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
33. Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
Wu Z; Peng Y; Xiong L; Wang J; Li Z; Ning K; Deng M; Wang N; Wei W; Li Z; Dong P; Yu C; Zhou F; Zhang Z
Cancer Med; 2022 Oct; 11(19):3674-3686. PubMed ID: 35476809
[TBL] [Abstract][Full Text] [Related]
34. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
35. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
36. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
37. The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis.
Wang Y; Peng M; Zhong Y; Xiong W; Zhu L; Jin X
Oncogene; 2023 Mar; 42(13):952-966. PubMed ID: 36732658
[TBL] [Abstract][Full Text] [Related]
38. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).
Quan J; Bai Y; Yang Y; Han EL; Bai H; Zhang Q; Zhang D
BMC Cancer; 2021 Jul; 21(1):814. PubMed ID: 34266404
[TBL] [Abstract][Full Text] [Related]
40. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
